Biotech news for Friday, June 26, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
alexsl Tonix Pharmaceuticals ( TNXP ) and MapLight Therapeutics ( MPLT ) traded higher on Thursday after Raymond James launched their coverage, issuing Strong Buy recommendations, with $26 and $46 per share targets, respectively, citing upcoming catalysts. Reg…
Wall Street advanced on Thursday after Micron Technology posted robust quarterly results, while traders digested fresh May inflation data for signals on the Federal Reserve's next policy moves. Here are some of Thursday's biggest stock movers: Biggest stock ga…
Michail_Petrov-96 Kymera Therapeutics ( KYMR ) added ~10% in the premarket on Thursday after announcing an expedited timeline to share topline data from a mid-stage trial for KT-621, its experimental therapy for atopic dermatitis (eczema). The global Phase 2b…
anusorn nakdee Plus Therapeutics ( PSTV ) shares rose in early premarket trading after its subsidiary CNSide Diagnostics announced an agreement with Elevance Health ( ELV ) to expand coverage for a cancer screening test. The national agreement allows members o…
ProQR Therapeutics ( PRQR ) has priced a registered direct offering of 27.6M ordinary shares at $1.81 per share, expecting to raise about $50M in gross proceeds before expenses. Separately, Eli Lilly ( LLY ), an existing shareholder and strategic partner, has…
ProQR Therapeutics ( PRQR ) shares gained in the premarket on Thursday after the Dutch biotech announced encouraging data from a Phase 1 trial for AX-0810, an experimental therapy for liver diseases. The company said that the trial for healthy volunteers indic…
canart7 ARS Pharmaceuticals ( SPRY ) shares plunged 23% in after-hours trading on Wednesday after the company said its neffy nasal spray failed to secure commercial insurance coverage. The company said no new commercial formulary additions or coverage decision…
Ionis Pharmaceuticals ( IONS ) Wednesday reported that it has entered into a license agreement with Recordati ( RICFY ), under which Recordati obtained exclusive rights to develop and commercialize zilganersen, an investigational RNA-targeted medicine for Alex…
Taysha Gene Therapies ( TSHA ) shares slumped 9.2% after-hours on Wednesday after pricing of an underwritten public offering of its common stock and pre-funded warrants, aiming to bring in approximately $200M in gross proceeds before underwriting discounts and…
Sundry Photography The US FDA has approved Gilead Sciences' ( GILD ) Trodelvy (s acituzumab govitecan) as a first-line treatment as monotherapy and in combination with Merck's ( MRK ) Keytruda (pembrolizumab) for triple-negative breast cancer. The monotherapy…
Taysha Gene Therapies ( TSHA ) announced an underwritten public offering targeting $200M through the sale of common stock and pre-funded warrants. All securities in the offering will be issued and sold by the company. Taysha plans to grant underwriters a 30-da…
eXoZymes ( EXOZ ) on Wednesday said it has received a Notice of Award from the National Institute of General Medical Sciences of the National Institutes of Health for a Phase IIB Small Business Innovation Research grant totaling $2.02M. The NIH funded work is…
piyaset/iStock via Getty Images The US FDA has approved an indicational indication for Ionis Pharmaceuticals' ( IONS ) Tryngolza (olezarsen) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia. The therapy is n…
Passage Bio ( PASG ) and Remix Therapeutics on Wednesday said they have entered into a definitive merger agreement to combine in an all-stock transaction. Upon completion of the transaction, the combined company plans to operate under the name Remix Therapeuti…
Shares of Natera ( NTRA ) added ~11% on Wednesday after Japan’s Pharmaceuticals and Medical Devices Agency approved the company’s colorectal cancer test, Signatera. The approval permits Austin, Texas-based Natera ( NTRA ) and its business partner SRL, Inc. to…
The U.S. FDA is fast reversing decisions made under former commissioner Marty Makary, especially those related to rare-disease therapies. Biotechs UniQure ( QURE ) and Regenxbio ( RGNX ) have become the latest beneficiaries of the regulatory U-turn, with many…
Anti-inflammatory drug developer Spyre Therapeutics ( SYRE ) lost ~10% on Wednesday, potentially on track to record its biggest one-day decline in more than a year after its director, Michael Henderson, sold $2M worth of company stock. The biotech executive so…